Kronik B hepatitli çocuklarda interferon tedavisinin hematolojik yan etkileri

Çocuklarda kronik hepatit B tedavisinde standart tedavi şekli Interferon tedavisidir. Genellikle iyi tolère edilmesine rağmen interferonun birkaç yan etkisi vardır ve bunlardan biri de kemik iliği süpresyonudur. Çalışmamızın amacı 6 ay süreyle 5-10 MÜ/m2 dozunda interleron ile tedavi edilen kronik B hepatitli 40 çocukta (32 erkek; yaş aralığı 4-15 yaş) alfa interferonun hematolojik yan etkilerini değerlendirmekti. Tedavi sırasında periferik kan hücrelerinde görülen en önemli düşüşler tedavinin ilk ve ikinci ayında gözlendi. Interferon dozu ile periferik kan hücrelerindeki düşüş miktarları arasında pozitif bir korelasyon vardı. Hastaların hiçbirinde lökopeni ya da trombositopeni nedeniyle interferon dozu azaltılmadı. Sonuçta çocuklarda interleron ile yapılan kronik hepatit tedavisinde hematolojik yan etkilerin tedavinin devamı için bir engel oluşturmadığı görüşüne varıldı.

The hematological side effects of alpha-interferon therapy in children with chronic viral hepatitis

Interferon is standard therapy for chronic viral hepatitis in children. Although it is usually tolerated, there are a lot of side effects;-of interleron, as the bone marrow suppression is one of them. The aim of this study was to evaluate the hematological side effects of alpha-interferon in 40 consecutive children (32 males; age range, 4 to 15 years) affected by chronic hepatitis B treated with 5-10 MU/m2 for 6 months. The lowest peripheral blood cells counts were observed between the first and second month of therapy. Dosage of Interferon was directly correlated with bone marrow suppression rate. The interferon dosage was reduced in none of them, because of leucopenia or thrombocytopenia. As a result; in therapy of chronic viral hepatitis B with interferon, hematological side effect is not a handicap for continuation of the therapy in children.

___

1. Conjeevaram HS. Therapy for chronic hepatitis B: nucleoside analogues in adult and pediatric patients. Acta Gastroenterol Belg 1998; 61: 224-227. 2. Jara P, Bortolotti F. Interferon-_____* treatment of chronic hepatitis B in childhood: a consensus advice based on experience in European children. J Pediatr Gastroenterol Nutr 1999; 29: 163-170. 3. Van Damme P, Vellinga A. Epidemiology of hepatitis B and C in Europe. Acta Gastroenterol Belg 1998; 61: 175-182. 4. Dinçer D, Demir K, Kaymakoğlu S, et al. Kronik viral hepatlt tedavisinde interferonun hematolojik parametrelere etkisi. Viral Hepatit Derg 2000; 3: L72-174. 5. Raffaele I, Pasqualina P, Salvatore B, et al. Side effects of a-interferon therapy and iippact on health-related quality of life in children with chronic viral hepatitis. Pediatr Infect Dis J 1997; 16: 984-990. 6. Jonas MM, Ott MJ, Nelson SP, et al. Interferon-alpha treatment of chronic hepatitis C virus infection in children. Pediatr Infect Dis J 1998; 17: 241-246. 7. Mercedes RM, Maria JR, Inmaculada C, et al. Treatment of children with chronic hepatitis C with recombLıant interferon-a: a pilot study. Hepatology 1992; 16: 882-885. 8. Moreno MR, Jimenez J, Porres JC, et al. A controlled trial of recombinant interferon-alpha in Caucasian children with chronic hepatitis B. Digestion 1990; 45: 26-33. 9. Gürakan F, Koçak N, Özen H, et al. Comparison of standard and high dosage recombinant interferon alpha 2b for treatment of children with chronic hepatitis B infection. Pediatr Infect Dis J 2000; 19: 52-56. 10. Fujisawa T, Komatsu H, Inoi A, et al. Long-terme outcome of chronic hepatitis B in adolescents or young adults in follow-up from childhood. J Pediatr Gastroenterol Nutr 2000; 30: 201-206.
Ondokuz Mayıs Üniversitesi Tıp Dergisi (. Journal of Experimental and Clinical Medicine)-Cover
  • ISSN: 1300-2996
  • Yayın Aralığı: Yılda 4 Sayı
  • Başlangıç: 2018